126 related articles for article (PubMed ID: 19074216)
1. Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
Antón A; Ruiz A; Seguí MA; Calvo L; Muñoz M; Lao J; Sancho F; Fernández L
Ann Oncol; 2009 Mar; 20(3):454-9. PubMed ID: 19074216
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
Antón A; Ruiz A; Plazaola A; Calvo L; Seguí MA; Santaballa A; Muñoz M; Sánchez P; Miguel A; Carrasco E; Lao J; Camps J; Alfaro J; Antolín S; Cámara MC
Ann Oncol; 2011 Jan; 22(1):74-79. PubMed ID: 20603435
[TBL] [Abstract][Full Text] [Related]
3. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
Coudert BP; Arnould L; Moreau L; Chollet P; Weber B; Vanlemmens L; Moluçon C; Tubiana N; Causeret S; Misset JL; Feutray S; Mery-Mignard D; Garnier J; Fumoleau P
Ann Oncol; 2006 Mar; 17(3):409-14. PubMed ID: 16332965
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Coudert BP; Largillier R; Arnould L; Chollet P; Campone M; Coeffic D; Priou F; Gligorov J; Martin X; Trillet-Lenoir V; Weber B; Bleuse JP; Vasseur B; Serin D; Namer M
J Clin Oncol; 2007 Jul; 25(19):2678-84. PubMed ID: 17515572
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.
Uriarte-Pinto M; Escolano-Pueyo Á; Gimeno-Ballester V; Pascual-Martínez O; Abad-Sazatornil MR; Agustín-Ferrández MJ
Int J Clin Pharm; 2016 Apr; 38(2):446-53. PubMed ID: 26951122
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients.
Mrózek E; Rhoades CA; Allen J; Hade EM; Shapiro CL
Ann Oncol; 2005 Jul; 16(7):1087-93. PubMed ID: 15849219
[TBL] [Abstract][Full Text] [Related]
8. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
Venturini M; Bighin C; Puglisi F; Olmeo N; Aitini E; Colucci G; Garrone O; Paccagnella A; Marini G; Crinò L; Mansutti M; Baconnet B; Barbato A; Del Mastro L
Breast; 2010 Oct; 19(5):333-8. PubMed ID: 20185313
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
Amadori D; Milandri C; Comella G; Saracchini S; Salvagni S; Barone C; Bordonaro R; Gebbia V; Barbato A; Serra P; Gattuso D; Nanni O; Baconnet B; Gasparini G
Eur J Cancer; 2011 Sep; 47(14):2091-8. PubMed ID: 21665463
[TBL] [Abstract][Full Text] [Related]
12. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
Montemurro F; Choa G; Faggiuolo R; Sperti E; Capaldi A; Donadio M; Minischetti M; Salomone A; Vietti-Ramus G; Alabiso O; Aglietta M
Am J Clin Oncol; 2003 Feb; 26(1):95-7. PubMed ID: 12576933
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
Burris HA
Semin Oncol; 2001 Feb; 28(1 Suppl 3):38-44. PubMed ID: 11301373
[TBL] [Abstract][Full Text] [Related]
14. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
Sparano JA; Malik U; Rajdev L; Sarta C; Hopkins U; Wolff AC
J Clin Oncol; 2001 Jun; 19(12):3117-25. PubMed ID: 11408509
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
[TBL] [Abstract][Full Text] [Related]
18. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
Rom J; von Minckwitz G; Eiermann W; Sievert M; Schlehe B; Marmé F; Schuetz F; Scharf A; Eichbaum M; Sinn HP; Kaufmann M; Sohn C; Schneeweiss A
Ann Oncol; 2008 Oct; 19(10):1698-705. PubMed ID: 18477581
[TBL] [Abstract][Full Text] [Related]
19. Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study.
Sato N; Sano M; Tabei T; Asaga T; Ando J; Fujii H; Yamamoto N; Kurosumi M; Inoue K; Kimura M
Breast Cancer; 2006; 13(2):166-71. PubMed ID: 16755112
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
